Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen

Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments